Haemonetics (HAE) Jumps 17% as CSL Plans Full U.S. Rollout

undefined

Haemonetics shares rose as much as 17% premarket Thursday after CSL said it will deploy NexSys PCS plasma devices at all U.S. centers by the end of 2027.

Lead

What Did CSL Announce?

CSL confirmed it will move its U.S. plasma centers onto Haemonetics' NexSys PCS devices with Persona PLUS technology and the related single-use disposables. The two companies signed a non-exclusive supply agreement on August 18, 2026. At that point, Haemonetics said CSL would switch only a portion of its U.S. centers, with scope and timing undecided.

Thursday's update widened that scope to the whole U.S. footprint and set an end date. The agreement is non-exclusive, so CSL can keep other equipment suppliers. Both scope and timing remain subject to change under the contract terms.

Why Did Haemonetics Shares Jump?

Shares jumped because the update turns a partial, open-ended supply arrangement into a defined, network-wide deployment. It also reverses a loss that has weighed on the stock for years. In 2021, CSL said it would not renew its U.S. supply agreement with Haemonetics. At the time, CSL's U.S. business contributed about $155 million of Haemonetics revenue in fiscal 2024.

The economics of the deal depend heavily on disposables. Each donor session uses single-use sets that are replaced every time, so every installed device generates recurring revenue. A full rollout across one of the world's largest plasma collectors would therefore lift disposables volume well beyond the equipment itself.

What Does It Mean for Haemonetics' Plasma Business?

The deal restores a major customer to Haemonetics' plasma franchise, which supplies collection systems to manufacturers of therapies for rare and chronic diseases. The company said it is not updating its fiscal 2027 guidance at this time. Management plans to quantify the expected financial impact during its second-quarter fiscal 2027 earnings call in November 2026.

For CSL, the move consolidates its U.S. donation operations on a single platform. That typically simplifies training, maintenance and supply logistics across a network of hundreds of centers. The company has not detailed the cost or the phasing of the switch.

Market Reaction

The premarket move was among the sharpest in the U.S. healthcare equipment space on Thursday. Reported gains ranged from roughly 13% to 17% depending on the time of the reading, as early indications settled. The scale of the reaction reflects how much the 2021 non-renewal had been priced into the stock, and how limited the August disclosure was. At that time, the lack of a committed scope and timeline left the revenue contribution hard to model.

What Comes Next for the CSL Rollout?

The next checkpoint is the November earnings call, where Haemonetics is expected to outline revenue timing, device placements and any change to its full-year outlook. Phasing will matter: a back-loaded 2027 installation schedule would push most of the disposables benefit into fiscal 2028. Contract flexibility is the main risk to the thesis, since the agreement allows CSL to adjust scope and timing.

Outlook

CSL's commitment to a network-wide rollout by the end of 2027 gives Haemonetics a clearer path to recovering a customer it lost in 2021. The financial effect remains unquantified until the November earnings call, and the non-exclusive structure leaves some uncertainty over final volumes.